News articles about Hologic (NASDAQ:HOLX) have been trending positive this week, according to Accern Sentiment. The research firm identifies positive and negative media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Hologic earned a news impact score of 0.28 on Accern’s scale. Accern also assigned news coverage about the medical equipment provider an impact score of 46.0083745769373 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Here are some of the news articles that may have impacted Accern Sentiment’s analysis:
- Gabelli Weighs in on Hologic, Inc.’s FY2018 Earnings (HOLX) (americanbankingnews.com)
- Contrasting Hologic (HOLX) and Illumina (ILMN) (americanbankingnews.com)
- Hologic Announces European CE Mark for Brevera Breast Biopsy System with CorLumina Imaging Technology (dotmed.com)
- Hologic Announces European CE Mark for Brevera® Breast Biopsy System with CorLumina® Imaging Technology (aboutpharma.com)
- Hologic Sees Q1 Revenue Above Guidance Range (finanznachrichten.de)
HOLX has been the subject of a number of research reports. Royal Bank of Canada reiterated a “hold” rating and set a $42.00 target price on shares of Hologic in a research report on Friday, September 22nd. Needham & Company LLC reiterated a “buy” rating and set a $50.00 target price on shares of Hologic in a research report on Monday, October 2nd. Zacks Investment Research lowered shares of Hologic from a “hold” rating to a “sell” rating in a research report on Tuesday, October 3rd. Stifel Nicolaus restated a “buy” rating and issued a $45.00 price objective (down from $48.00) on shares of Hologic in a research report on Monday, October 9th. Finally, Jefferies Group restated a “buy” rating and issued a $44.00 price objective (down from $49.00) on shares of Hologic in a research report on Tuesday, October 10th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $48.79.
Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Wednesday, November 8th. The medical equipment provider reported $0.50 EPS for the quarter, topping the consensus estimate of $0.49 by $0.01. Hologic had a net margin of 24.70% and a return on equity of 21.69%. The firm had revenue of $802.90 million for the quarter, compared to the consensus estimate of $792.54 million. During the same period last year, the firm posted $0.52 earnings per share. The business’s revenue was up 10.5% compared to the same quarter last year. sell-side analysts predict that Hologic will post 2.13 EPS for the current fiscal year.
In other news, VP Karleen Marie Oberton sold 1,256 shares of the business’s stock in a transaction on Wednesday, November 8th. The shares were sold at an average price of $39.29, for a total transaction of $49,348.24. Following the sale, the vice president now owns 9,406 shares in the company, valued at approximately $369,561.74. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Elaine Ullian sold 9,282 shares of the business’s stock in a transaction on Monday, November 13th. The shares were sold at an average price of $40.50, for a total transaction of $375,921.00. The disclosure for this sale can be found here. Insiders sold 12,099 shares of company stock worth $487,223 in the last 90 days. Company insiders own 0.79% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Positive Media Coverage Somewhat Unlikely to Affect Hologic (HOLX) Stock Price” was originally reported by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this piece on another domain, it was illegally stolen and republished in violation of US and international copyright legislation. The original version of this piece can be accessed at https://stocknewstimes.com/2018/01/12/hologic-holx-earns-daily-media-impact-score-of-0-28.html.
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.